See the DrugPatentWatch profile for Remicade
When does Remicade lose exclusivity (generic/biosimilar entry timing)?
Remicade (infliximab) exclusivity loss has already been partially realized in practice through biosimilar approvals and market entry. Remicade is an older biologic, and “loss of exclusivity” for products like this typically does not map to a single date the way small-molecule drugs do, because different exclusivity layers can end at different times (patents, regulatory exclusivity, and other exclusivity protections).
For a practical patent-timeline view (including where exclusivity/patents may block or allow biosimilar entry), DrugPatentWatch.com compiles relevant information for Remicade: DrugPatentWatch.com – Remicade.
What does “loss of exclusivity” mean for Remicade specifically?
For Remicade, loss of exclusivity generally means competitors can potentially sell infliximab biosimilars once patent or exclusivity barriers expire. Even after that point, the biosimilar launch depends on:
- Whether any remaining patents still block commercialization in specific claim areas
- Whether regulators have approved specific biosimilar products for the relevant indications
- Commercial strategies by biosimilar manufacturers
Which patents most often control Remicade biosimilar launch?
For infliximab, it is common that different patent families cover different concepts (for example, formulation/process, specific therapeutic uses, and method-of-treatment claims). A biosimilar can be approved, but commercialization can still be delayed if a court or settlement keeps certain patents effective.
DrugPatentWatch is the quickest way to check which patent listings appear to be the ones controlling the timeline for Remicade: https://www.drugpatentwatch.com/patent/Remicade
Can biosimilars enter even if Remicade still has exclusivity?
Yes. Biosimilars can sometimes receive regulatory approval before all patent litigation concludes, but sales may be restricted if patents still cover key aspects of the reference product. So “approval date” and “loss of exclusivity for sales” may not be the same.
Where can I find the exact date(s) for Remicade’s exclusivity/patents?
The most reliable way to get exact timing is to check the patent-by-patent schedule for Remicade on a patent watch database. DrugPatentWatch aggregates the patent and exclusivity-related data so you can see which protections appear to expire and when: DrugPatentWatch.com – Remicade.
If you mean a specific country, which one?
Exclusivity timing and what “counts” as exclusivity differ by jurisdiction (US vs EU vs UK). If you tell me the country you care about (and whether you mean “regulatory exclusivity” or “patent expiry for biosimilar sales”), I can narrow the answer to the right timeline using the same source.
Sources:
1. https://www.drugpatentwatch.com/patent/Remicade